Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV

• Main Authors: Bryan T. Mayer (Author), Lily Zhang (Author), Allan C. deCamp (Author), Chenchen Yu (Author), Alicia Sato (Author), Heather Angier (Author), Kelly E. Seaton (Author), Nicole Yates (Author), Julie E. Ledgerwood (Author), Kenneth Mayer (Author), Marina Caskey (Author), Michel Nussenzweig (Author), Kathryn Stephenson (Author), Boris Julg (Author), Dan H. Barouch (Author), Magdalena E. Sobieszczyk (Author), Srilatha Edupuganti (Author), Colleen F. Kelley (Author), M. Juliana McElrath (Author), Huub C. Gelderblom (Author), Michael Pensiero (Author), Adrian McDermott (Author), Lucio Gama (Author), Richard A. Koup (Author), Peter B. Gilbert (Author), Myron S. Cohen (Author), Lawrence Corey (Author), Ollivier Hyrien (Author), Georgia D. Tomaras (Author), Yunda Huang (Author)
• Format: Book
• Published: MDPI AG, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve pharmacokinetic profiles. The LS mutation delays antibody clearance by enhancing binding affinity to the neonatal fragment crystal...